Lates News

Lilly (LLY.US) and Novo Nordisk (NVO.US) both announced a straight line increase and reached an agreement with the US government to lower the price of GLP-1 while also obtaining a three-year tariff exemption. Senior officials of the Trump administration stated that approximately 10% of federal Medicare patients will be eligible to expand the use of GLP-1.